The real effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against COVID-19 – Medical news

Real-world effectiveness of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against severe infections and diseases in children and adolescents


The effectiveness of the BNT162b2 vaccine in pediatrics was assessed in randomized trials even before the introduction of the Omicron variant. The long-term sustainability of vaccine protection in this population during the Omicron period remains limited.


To evaluate the effectiveness of BNT162b2 in preventing severe infection and disease with different strains of the SARS-CoV-2 virus in previously uninfected children and adolescents.


Comparative effectiveness study considering unannounced vaccination in three study cohorts: adolescents (12 to 20 years) during the Delta phase and children (5 to 11 years) and adolescents (12 to 20 years) during the Omicron phase. .


National Pediatric Health Systems Collaborative (PEDSnet).


77,392 adolescents (45,007 vaccinated) during the Delta phase and 111,539 children (50,398 vaccinated) and 56,080 adolescents (21,180 vaccinated) during the Omicron phase.


First dose of BNT162b2 vaccine versus no COVID-19 vaccine.


Outcomes of interest included documented infection, COVID-19 disease severity, intensive care unit (ICU) admission, and cardiac complications. Efficacy was estimated as (1-relative risk)*100, with confounders balanced by propensity score stratification.


During the Delta period, the estimated efficacy of BNT162b2 vaccine was 98.4% (95% CI: 98.1–98.7%) against documented infection among adolescents, with no statistically significant decline after the first dose.

Analysis of cardiac complications did not reveal a statistically significant difference between the vaccinated and unvaccinated groups.

During the period of use of Omicron, the effectiveness against documented infections among children was estimated at 74.3% (CI 72.2% to 76.2%). Higher efficacy rates were observed for moderate to severe COVID-19 (75.5% (CI 69.0% to 81.0%)) and ICU admission with COVID-19 (84.9% (CI 64.8% to 93.5%)).

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button